Skip to main content
Advanced Technical IVT

tumor suppressor haploinsufficiency

Pronunciation: HAP-low-in-suh-FISH-en-see

A condition where loss of one functional copy of a tumor suppressor gene reduces cellular growth control below the threshold needed for normal function.

Full Definition

Tumor suppressor haploinsufficiency occurs when a single functional copy of a tumor suppressor gene is insufficient to maintain normal cellular growth control, even without complete loss of the second allele. This mechanism differs from the classical 'two-hit hypothesis' where both copies must be inactivated for cancer predisposition. Haploinsufficient tumor suppressors include genes like TP53, PTEN, and NF1, where heterozygous loss can contribute to tumorigenesis. In cancer genomics reporting, recognition of haploinsufficiency is crucial for interpreting the clinical significance of heterozygous deletions and nonsense mutations in these genes. This concept has important implications for cancer risk assessment and therapeutic targeting.

Usage

Usage note: Emphasize distinction from classical two-hit model; important for variant interpretation.

In Context

  • "The heterozygous PTEN deletion was classified as pathogenic due to tumor suppressor haploinsufficiency." — Genetic counseling report
  • "Evidence for haploinsufficiency was supported by the dosage-sensitive nature of this tumor suppressor." — Molecular pathology assessment

Also known as

haplosufficiency failure dosage sensitivity

Contrasted with

complete knockout two-hit inactivation

Don't confuse with

loss of heterozygosity tumor suppressor gene

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON